Effective intervention for mild cognitive impairment (MCI) is key for preventing dementia. As a neuroprotective agent, butylphthalide has the potential to treat MCI due to Alzheimer disease (AD). However, the pharmacological mechanism of butylphthalide from the brain network perspective is not clear. Therefore, we aimed to investigate the multimodal brain network changes associated with butylphthalide treatment in MCI due to AD. A total of 270 patients with MCI due to AD received either butylphthalide or placebo at a ratio of 1:1 for 1 year. Effective treatment was defined as a decrease in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) > 2.5. Brain networks were constructed using T1-magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. A support vector machine was applied to develop predictive models. Both treatment (drug vs. placebo)-time interactions and efficacy (effective vs. ineffective)-time interactions were detected on some overlapping structural network metrics. Simple effects analyses revealed a significantly increased global efficiency in the structural network under both treatment and effective treatment of butylphthalide. Among the overlapping metrics, an increased degree centrality of left paracentral lobule was significantly related to poorer cognitive improvement. The predictive model based on baseline multimodal network metrics exhibited high accuracy (88.93%) of predicting butylphthalide's efficacy. Butylphthalide may restore abnormal organization in structural networks of patients with MCI due to AD, and baseline network metrics could be predictive markers for therapeutic efficacy of butylphthalide. This study was registered in the Chinese Clinical Trial Registry (Registration Number: ChiCTR1800018362, Registration Date: 2018-09-13).

To evaluate the accuracy of ChatGPT-4o in identifying magnetic resonance imaging (MRI) findings and diagnosing brain tumors by comparing its performance with that of experienced radiologists. This retrospective study included 46 patients with pathologically confirmed brain tumors who underwent preoperative MRI between January 2021 and October 2024. Two experienced radiologists and ChatGPT 4o independently evaluated the anonymized MRI images. Eight questions focusing on MRI sequences, lesion characteristics, and diagnoses were answered. ChatGPT-4o's responses were compared to those of the radiologists and the pathology outcomes. Statistical analyses were performed, which included accuracy, sensitivity, specificity, and the McNemar test, with p<0.05 considered to indicate a statistically significant difference. ChatGPT-4o successfully identified 44 of the 46 (95.7%) lesions; it achieved 88.3% accuracy in identifying MRI sequences, 81% in perilesional edema, 79.5% in signal characteristics, and 82.2% in contrast enhancement. However, its accuracy in localizing lesions was 53.6% and that in distinguishing extra-axial from intra-axial lesions was 26.3%. As such, ChatGPT-4o achieved success rates of 56.8% and 29.5% for differential diagnoses and most likely diagnoses when compared to 93.2-90.9% and 70.5-65.9% for radiologists, respectively (p<0.005). ChatGPT-4o demonstrated high accuracy in identifying certain MRI features but underperformed in diagnostic tasks in comparison with the radiologists. Despite its current limitations, future updates and advancements have the potential to enable large language models to facilitate diagnosis and offer a reliable second opinion to radiologists.

Brain Tumours are highly complex, particularly when it comes to their initial and accurate diagnosis, as this determines patient prognosis. Conventional methods rely on MRI and CT scans and employ generic machine learning techniques, which are heavily dependent on feature extraction and require human intervention. These methods may fail in complex cases and do not produce human-interpretable results, making it difficult for clinicians to trust the model's predictions. Such limitations prolong the diagnostic process and can negatively impact the quality of treatment. The advent of deep learning has made it a powerful tool for complex image analysis tasks, such as detecting brain Tumours, by learning advanced patterns from images. However, deep learning models are often considered "black box" systems, where the reasoning behind predictions remains unclear. To address this issue, the present study applies Explainable AI (XAI) alongside deep learning for accurate and interpretable brain Tumour prediction. XAI enhances model interpretability by identifying key features such as Tumour size, location, and texture, which are crucial for clinicians. This helps build their confidence in the model and enables them to make better-informed decisions. In this research, a deep learning model integrated with XAI is proposed to develop an interpretable framework for brain Tumour prediction. The model is trained on an extensive dataset comprising imaging and clinical data and demonstrates high AUC while leveraging XAI for model explainability and feature selection. The study findings indicate that this approach improves predictive performance, achieving an accuracy of 92.98% and a miss rate of 7.02%. Additionally, interpretability tools such as LIME and Grad-CAM provide clinicians with a clearer understanding of the decision-making process, supporting diagnosis and treatment. This model represents a significant advancement in brain Tumour prediction, with the potential to enhance patient outcomes and contribute to the field of neuro-oncology.

Malignant cerebral edema (MCE) is a significant complication following endovascular thrombectomy (EVT) in the treatment of acute ischemic stroke. This study aimed to develop and validate a deep learning-assisted diagnosis model based on the hyperattenuated imaging marker (HIM), characterized by hyperattenuation on head non-contrast computed tomography immediately after thrombectomy, to facilitate radiologists in predicting MCE in patients receiving EVT. This study included 271 patients, with 168 in the training cohort, 43 in the validation cohort, and 60 in the prospective internal test cohort. Deep learning models including ResNet 50, ResNet 101, ResNeXt50_32×4d, ResNeXt101_32×8d, and DenseNet 121 were constructed. The performance of senior and junior radiologists with and without optimal model assistance was compared. ResNeXt101_32×8d had the best predictive performance, the analysis of the receiver operating characteristic curve indicated an area under the curve (AUC) of 0.897 for the prediction of MCE in the validation group and an AUC of 0.889 in the test group. Moreover, with the assistance of the model, radiologists exhibited a significant improvement in diagnostic performance, the AUC increased by 0.137 for the junior radiologist and 0.096 for the junior radiologist respectively. Our study utilized the ResNeXt-101 neural network, combined with HIM, to validate a deep learning model for predicting MCE post-EVT. The developed deep learning model demonstrated high discriminative ability, and can serve as a valuable adjunct to radiologists in clinical practice.

With the increasing prevalence of mental illness, accurate clinical diagnosis of mental illness is crucial. Compared with MRI, CT has the advantages of wide application, low price, short scanning time, and high patient cooperation. This study aims to construct a deep learning (DL) model based on CT images to make identification of bipolar disorder (BD) and schizophrenia (SZ). A total of 506 patients (BD = 227, SZ = 279) and 179 healthy controls (HC) was collected from January 2022 to May 2023 at two hospitals, and divided into an internal training set and an internal validation set according to a ratio of 4:1. An additional 65 patients (BD = 35, SZ = 30) and 40 HC were recruited from different hospitals, and served as an external test set. All subjects accepted the conventional brain CT examination. The DenseMD model for identify BD and SZ using multiple instance learning was developed and compared with other classical DL models. The results showed that DenseMD performed excellently with an accuracy of 0.745 in the internal validation set, whereas the accuracy of the ResNet-18, ResNeXt-50, and DenseNet-121model was 0.672, 0.664, and 0.679, respectively. For the external test set, DenseMD again outperformed other models with an accuracy of 0.724; however, the accuracy of the ResNet-18, ResNeXt-50, and DenseNet-121model was 0.657, 0.638, and 0.676, respectively. Therefore, the potential of DL models for identification of BD and SZ based on brain CT images was established, and identification ability of the DenseMD model was better than other classical DL models.

Our primary aim with this study was to build a patient-level classifier for stroke territory in DWI using AI to facilitate fast triage of stroke to a dedicated stroke center. A retrospective collection of DWI images of 271 and 122 consecutive acute ischemic stroke patients from two centers was carried out. Pretrained MobileNetV2 and EfficientNetB0 architectures were used to classify territorial subtypes as middle cerebral artery, posterior circulation, or watershed infarcts along with normal slices. Various input combinations using edge maps, thresholding, and hard attention versions were explored. The effect of augmenting the three-channel inputs of pre-trained models on classification performance was analyzed. ROC analyses and confusion matrix-derived performance metrics of the models were reported. Of the 271 patients included in this study, 151 (55.7%) were male and 120 (44.3%) were female. One hundred twenty-nine patients had MCA (47.6%), 65 patients had posterior circulation (24%), and 77 patients had watershed (28.0%) infarcts for center 1. Of the 122 patients from center 2, 78 (64%) were male and 44 (34%) were female. Fifty-two patients (43%) had MCA, 51 patients had posterior circulation (42%), and 19 (15%) patients had watershed infarcts. The Mobile-Crop model had the best performance with 0.95 accuracy and a 0.91 mean f1 score for slice-wise classification and 0.88 accuracy on external test sets, along with a 0.92 mean AUC. In conclusion, modified pre-trained models may be augmented with the transformation of images to provide a more accurate classification of affected territory by stroke in DWI.

Brain tumor is a type of disease caused by uncontrolled cell proliferation in the brain leading to serious health issues such as memory loss and motor impairment. Therefore, early diagnosis of brain tumors plays a crucial role to extend the survival of patients. However, given the busy nature of the work of radiologists and aiming to reduce the likelihood of false diagnoses, advancing technologies including computer-aided diagnosis and artificial intelligence have shown an important role in assisting radiologists. In recent years, a number of deep learning-based methods have been applied for brain tumor detection and classification using MRI images and achieved promising results. The main objective of this paper is to present a detailed review of the previous researches in this field. In addition, This work summarizes the existing limitations and significant highlights. The study systematically reviews 60 articles researches published between 2020 and January 2024, extensively covering methods such as transfer learning, autoencoders, transformers, and attention mechanisms. The key findings formulated in this paper provide an analytic comparison and future directions. The review aims to provide a comprehensive understanding of automatic techniques that may be useful for professionals and academic communities working on brain tumor classification and detection.

Predicting long-term clinical outcomes based on the early DSC PWI MRI scan is valuable for prognostication, resource management, clinical trials, and patient expectations. Current methods require subjective decisions about which imaging features to assess and may require time-consuming postprocessing. This study's goal was to predict multilabel 90-day modified Rankin Scale (mRS) score in acute ischemic stroke patients by combining ensemble models and different configurations of radiomic features generated from Dynamic susceptibility contrast perfusion-weighted imaging. In Follow-up studies, a total of 70 acute ischemic stroke (AIS) patients underwent magnetic resonance imaging within 24 hours poststroke and had a follow-up scan. In the single study, 150 DSC PWI Image scans for AIS patients. The DRF are extracted from DSC-PWI Scans. Then Lasso algorithm is applied for feature selection, then new features are generated from initial and follow-up scans. Then we applied different ensemble models to classify between three classes normal outcome (0, 1 mRS score), moderate outcome (2,3,4 mRS score), and severe outcome (5,6 mRS score). ANOVA and post-hoc Tukey HSD tests confirmed significant differences in model style performance across various studies and classification techniques. Stacking models consistently on average outperformed others, achieving an Accuracy of 0.68 ± 0.15, Precision of 0.68 ± 0.17, Recall of 0.65 ± 0.14, and F1 score of 0.63 ± 0.15 in the follow-up time study. Techniques like Bo_Smote showed significantly higher recall and F1 scores, highlighting their robustness and effectiveness in handling imbalanced data. Ensemble models, particularly Bagging and Stacking, demonstrated superior performance, achieving nearly 0.93 in Accuracy, 0.95 in Precision, 0.94 in Recall, and 0.94 in F1 metrics in follow-up conditions, significantly outperforming single models. Ensemble models based on radiomics generated from combining Initial and follow-up scans can be used to predict multilabel 90-day stroke outcomes with reduced subjectivity and user burden.

Timely and precise identification of acute ischemic stroke (AIS) within 4.5 h is imperative for effective treatment decision-making. This study aims to construct a novel network that utilizes limited datasets to recognize AIS patients within this critical window. We conducted a retrospective analysis of 265 AIS patients who underwent both fluid attenuation inversion recovery (FLAIR) and diffusion-weighted imaging (DWI) within 24 h of symptom onset. Patients were categorized based on the time since stroke onset (TSS) into two groups: TSS ≤ 4.5 h and TSS > 4.5 h. The TSS was calculated as the time from stroke onset to MRI completion. We proposed a synchronized dual-stage network (SDS-Net) and a sequential dual-stage network (Dual-stage Net), which were comprised of infarct voxel identification and TSS classification stages. The models were trained on 181 patients and validated on an independent external cohort of 84 patients using metrics of area under the curve (AUC), sensitivity, specificity, and accuracy. A DeLong test was used to statistically compare the performance of the two models. SDS-Net achieved an accuracy of 0.844 with an AUC of 0.914 in the validation dataset, outperforming the Dual-stage Net, which had an accuracy of 0.822 and an AUC of 0.846. In the external test dataset, SDS-Net further demonstrated superior performance with an accuracy of 0.800 and an AUC of 0.879, compared to the accuracy of 0.694 and AUC of 0.744 of Dual-stage Net (P = 0.049). SDS-Net is a robust and reliable tool for identifying AIS patients within a 4.5-h treatment window using MRI. This model can assist clinicians in making timely treatment decisions, potentially improving patient outcomes.

Recent advancements in neuroimaging and machine learning have significantly improved our ability to diagnose and categorize isocitrate dehydrogenase (IDH)-wildtype glioblastoma, a disease characterized by notable tumoral heterogeneity, which is crucial for effective treatment. Neuroimaging techniques, such as diffusion tensor imaging and magnetic resonance radiomics, provide noninvasive insights into tumor infiltration patterns and metabolic profiles, aiding in accurate diagnosis and prognostication. Machine learning algorithms further enhance glioblastoma characterization by identifying distinct imaging patterns and features, facilitating precise diagnoses and treatment planning. Integration of these technologies allows for the development of image-based biomarkers, potentially reducing the need for invasive biopsy procedures and enabling personalized therapy targeting specific pro-tumoral signaling pathways and resistance mechanisms. Although significant progress has been made, ongoing innovation is essential to address remaining challenges and further improve these methodologies. Future directions should focus on refining machine learning models, integrating emerging imaging techniques, and elucidating the complex interplay between imaging features and underlying molecular processes. This review highlights the pivotal role of neuroimaging and machine learning in glioblastoma research, offering invaluable noninvasive tools for diagnosis, prognosis prediction, and treatment planning, ultimately improving patient outcomes. These advances in the field promise to usher in a new era in the understanding and classification of IDH-wildtype glioblastoma.